At present, it is generally recognized that patients with gastric and colorectal malignant tumors and MSI-H/dMMR in tumor tissues have better curative effect and higher benefit rate when using PD-1/PD-L1 inhibitor. This evidence concerns the gene CD274 and colorectal cancer.